نتایج جستجو برای: ژن vkorc1
تعداد نتایج: 16292 فیلتر نتایج به سال:
بیمارن در پاسخ به دارودرمانی به طور گسترده ای با هم متفاوتند. واریانتهای ژنتیکی از ی سو اثرات مفید و از سوی دیگر عوارض جانبی جدی و غیرمنتظره ای دارند.تغییرات ژنتیک در پاسخ به داروها به فارماکونتیک برمی گردد. اغلب، پایه ی (snps) مسئول آنزیم متابولیک برای تخریب دارو در ارگانیسم های انسانی است. یکی از اهداف عمده تحقیقات فارماکوژنتیک، خانواده ژنی cyp450 می باشد که تعدادی از پروتئین های دارای هم- تی...
Cytochrome P450 oxidoreductase (POR) is required for drug metabolism by all microsomal cytochrome P450 enzymes. The aim of this study was to investigate whether any of the common single nucleotide polymorphisms (SNPs) in the POR gene and its flanking intergenic sequences correlate with interindividual variations in the warfarin maintenance dose (which is determined partly by rates of warfarin m...
BACKGROUND A C1173T polymorphism in intron 1 of the VKORC1 gene has been claimed to determine the interindividual variability in the response to vitamin K antagonist therapy (VKA), but it is unknown whether it also influences bleeding risk. We aimed to confirm the relationship between C1173T status and phenprocoumon or acenocoumarol use, and to examine the risk of severe bleeding for the variou...
The identification of CYP2C9 and VKORC1 genes has strongly stimulated the research on pharmacogenetics of coumarins in the last decade. We assessed the combined influence of CYP2C9 *2 and *3, and VKORC1 c.-1639G>A, 497C>G, and 1173C>T variants, on acenocoumarol dosage using a novel algorithm approach, in 193 outpatients who had achieved stable anticoagulation. We constructed an "acenocoumarol-d...
BACKGROUND Polymorphisms of the CYP2C9 (cytochrome P450, family 2, subfamily C, polypeptide 9) gene (CYP2C9*2, CYP2C9*3) and the VKORC1 (vitamin K epoxide reductase complex, subunit 1) gene (-1639G>A) greatly impact the maintenance dose for the drug warfarin. Prescreening patients for their genotypes before prescribing the drug facilitates a faster individualized determination of the proper mai...
To reduce the risk of hemorrhage, experts advocate prescribing the anticipated therapeutic dose to patients who are beginning coumarin therapy, but until now there was no accurate way to estimate that dose. Using pharmacogenetics-based coumarin therapy, clinicians can now estimate the therapeutic dose by genotyping their patients for single nucleotide polymorphisms (SNPs) that affect coumarin m...
Well-characterized genes that affect warfarin metabolism (cytochrome P450 (CYP) 2C9) and sensitivity (vitamin K epoxide reductase complex 1 (VKORC1)) explain one-third of the variability in therapeutic dose before the international normalized ratio (INR) is measured. To determine genotypic relevance after INR becomes available, we derived clinical and pharmacogenetic refinement algorithms on th...
Warfarin, a coumarin vitamin K antagonist, is the most widely prescribed anticoagulant agent for the control and prevention of atrial fibrillation-related thrombus formation, stroke, and arterial and venous thrombembolism (Hirsh J et al., 1998). The recommend warfarin therapy consists of the lowest dose required to maintain the target international normalized ratio (INR) because of the drug’s n...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید